Strategic merger Leverage the merger between Selecta Biosciences and Cartesian Therapeutics to position joint offerings focused on RNA cell therapy for autoimmune diseases, creating cross-sell opportunities with researchers and biotechs seeking advanced immunotherapies.

Clinical pipeline Target opportunities around Cartesian’s lead candidate Descartes-08 and RNA cell therapy programs, offering translational and manufacturing support, and identify potential research collaborations or co-development arrangements with academic partners and biotech firms.

Financing signals Capital infusion from private financing signals readiness for accelerated projects; propose mid-stage partnership discussions, licensing, or milestone-based deals to de-risk and fund expanded manufacturing, trials, or platform optimization.

Immunotolerance platform Position ImmTOR and immune tolerance capabilities as enabling technologies for autoimmune therapies, exploring partnerships to improve safety profiles, reduce immunogenicity in gene/cell therapy pipelines, and broaden customer use-cases.

Operational scale Although mid-size with 11-50 employees, the combined entity may require CRO/CDMO support and manufacturing scale; offer end-to-end services, from vector production to GMP manufacturing, quality assurance, and regulatory affairs acceleration.